Case 1 HCC (uninfected)
|
Sorafenib (SD, 17.3 weeks)
|
PD-1 inhibitor (PD, 6.9 weeks)
|
Sorafenib (PR, 50.4 weeksb)
|
Case 2 HCC (Child-Pugh A Hepatitis B)
|
Oncolytic vaccine and sorafeniba (PD, 11.7 weeks)
|
FGFR inhibitor and PD-1 inhibitor (SD, 21.1 weeks)
|
Lenvatinib (PR, 18.0 weeks) Ramucirumab (PR, 24.0 weeks) XELOX (PD, 4.0 weeks)
|
Case 3 HCC (Child-Pugh A Hepatitis B)
|
None
|
PD-L1 inhibitor (SD, 31.0 weeks)
|
Sorafenib (PR, 14.7 weeks); Lenvatinib (PD, 7.0 weeks) Regorafenib (PD, 4.0 weeks)
|
Case 4 HCC (Child-Pugh A Hepatitis C)
|
None
|
PD-L1 inhibitor (SD, 12.2 weeks)
|
Sorafenib (CR, 65.4 weeksb)
|
Case 5 HCC (Child-Pugh A Hepatitis B)
|
None
|
PD-L1 inhibitor CTLA-4 inhibitor (PD, 16.4 weeks)
|
Lenvatinib (PR, 20.4 weeks) Pan-HER inhibitor (PD, 3.1 weeks) FGFR inhibitor (NE, 2.6 weeks)
|
Case 6 Rectal cancer
|
FOLFOX-Cetuximab ➔ deGramont-Cetuximab (PR, 55.9 weeks) FOLFIRI-Bevacizumab (PR, 55.6 weeks) Regorafenib (NE) FOLFIRI/Pan-Her inhibitor (NE) TAS-102 (PD, 9.6 weeks)
|
PD-1 inhibitor and MEK inhibitor (SD, 12.1 weeks)
|
FOLFIRI and cetuximab (PR, 39.1 weeks) FOLFOX and panitumumab (NE)
|